ReviewExploration (Beijing, China)2022
Engineered cancer cell membranes: An emerging agent for efficient cancer theranostics.
Review in Exploration (Beijing, China), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
39 citing papers in PubMed, 96 citations in OpenAlex.
- Tumor-Mimic Artificial Cell Integrated With In Situ Synthetic Biology for Testing of Antitumor Drug Sensitivity.Exploration (Beijing, China) · 2026Article
- Redox-modulating macrophage biohybrid nanoplatform for targeted RIPK1-PANoptosome suppression in ischemic stroke.Redox biology · 2026Article
- Cell membrane biomimetic nanoplatforms: a new strategy for immune escape and precision targeted therapy.Materials today. Bio · 2025Review
- Dual-Targeted Nanovesicles Induced Cancer Stem-Like Cell Differentiation to Sensitize Hepatocellular Carcinoma Radiotherapy.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- Janus Ag/Fe-HfOMaterials today. Bio · 2025Article
- Bioengineering Outer-Membrane Vesicles for Vaccine Development: Strategies, Advances, and Perspectives.Vaccines · 2025Review
- Biomembrane-coated nanosystems as next-generation delivery systems for the treatment of gastrointestinal cancers.Bioengineering & translational medicine · 2025Review
- Metal-phenolic networks specifically eliminate hypoxic tumors by instigating oxidative and proteotoxic stresses.Bioactive materials · 2025Article
- Bio-barrier-adaptable biomimetic nanomedicines combined with ultrasound for enhanced cancer therapy.Signal transduction and targeted therapy · 2025Article
- Induction of the p21/CDK6 pathway and alteration of the immune microenvironment by the stem cell marker CBX3 in melanoma.Stem cell research & therapy · 2025Article
- Recent development of micro-nano carriers for oral antineoplastic drug delivery.Materials today. Bio · 2025Review
- Janus-Structured Micro/Nanomotors: Self-Propelled Mechanisms and Biomedical Applications.Biomaterials research · 2025Review
- The role of manganese-based MRI contrast agents for cancer theranostics: Where do we stand in 2025?Theranostics · 2025Review
- A polymer nanogel-based therapeutic nanovaccine for prophylaxis and direct treatment of tumorsBioactive materials · 2025Article
- Nature's carriers: leveraging extracellular vesicles for targeted drug delivery.Drug delivery · 2024Review
- Photoresponsive Multirole Nanoweapon Camouflaged by Hybrid Cell Membrane Vesicles for Efficient Antibacterial Therapy of Pseudomonas aeruginosa-Infected Pneumonia and Wound.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2024Article
- Biomimetic Hydrogel Strategies for Cancer Therapy.Gels (Basel, Switzerland) · 2024Review
- A Novel PEtOx-Based Nanogel Targeting Prostate Cancer Cells for Drug Delivery.Macromolecular bioscience · 2024Article
- Cancer theragnostics: closing the loop for advanced personalized cancer treatment through the platform integration of therapeutics and diagnostics.Frontiers in bioengineering and biotechnology · 2024Review
- The clinical regimens and cell membrane camouflaged nanodrug delivery systems in hematologic malignancies treatment.Frontiers in pharmacology · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
For efficient cancer theranostics, surface modification of nanomaterials plays an important role in improving targeting ability and reducing the non-specific interactions with normal tissues. Recently, the biomimetic technology represented by coating of cancer cell membranes (CCMs) has been regarded as a promising method to strengthen the biocompatibility and targeting specificity of nanomaterials. Furthermore, the engineered CCMs (ECCMs) integrated with the natural biological properties of CCMs and specific functions from other cells or proteins have offered more possibilities in the field of cancer theranostics. Herein, the recent progresses in the design and preparation of ECCMs are summarized, and the applications of ECCMs in targeting delivery, activation of immunity, and detection of circulating tumor cells are reviewed. Finally, the current challenges and future perspectives with regard to the development of ECCMs are briefly discussed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.